Biotech Project Funding

Biotech Project Funding

 

Access to capital is a major hurdle for biotechnology companies of every size. That being said however COVID-19 and the urgency in finding a cure have opened up opportunities, making the biotech sector a very attractive space for investments. The sector’s growth potential seems encouraging, as forecasters expect demand for diagnostics and antibody tests to outstrip supply for the foreseeable future. At the time of writing, the coronavirus has already infected more than 4M globally, with death tolls around the world continuing to grow. Even governments that appeared to have tamed the disease have warned of resurgence.

Funding sources for biotech include but are not limited to:

 

1. Public Funding Resources;
2. Trade Resources;                                                                                                        
3. Universities;                                                                                                                                                         
4. Private Companies;                                                                                                                                     
5. Angel Investors;                                                                                                                                      
6. Venture Capital Firms;                                                                                                                                
7. Corporate Venture Funds;

 

Given the ever-growing amount of biotech companies seeking funding and the limited number of available biotech funding sources available what are biotech companies supposed to do to attract interest?, It is axiomatic that attracting initial interest to your biotech project greatly increases the odds that financing can be achieved. The ultimate question for the biotech business seeking capital to answer is” How do you attract that initial interest?”

 

Valenti Partners in association with its partners is pleased to be able to facilitate the acquisition of biotech project financing through our ability to create investment grade collateral through the UPPLIFT^TM Investment Strategy (“UPPLIFT^TM“). Our methodology provides investors in high-risk alternative investment opportunities the ability to invest with little risk relative to the types of investments. At the same time, it affords those biotech projects seeking financing with a solution that will facilitate their capital raises. Thus, resulting in a process that really takes the risk out of the investment for investors without the borrower incurring the substantial cost or administrative burden. By engaging us you differentiate yourself from your competitors and get the ability to obtain that critical first look at a very manageable cost.

 

Please feel free to reach out to me at valentipartners@gmail.com 718-266-3410 for more information.

 

Dominick M. Valenti

Dominick M. Valenti
Chief Executive Officer
Valenti Partners, LLC.